A publicly traded biotechnology company (TSX: ATE) exploiting a groundbreaking advance in inflammation science.
Employees: 11-50
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Verdex Cap... | verdexcapi... |
Mentions in press and media 2
| Date | Title | Description |
| 30.06.2020 | ANTIBE THERAPEUTICS INC. Antibe Therapeutics Announces Closing of $28.75 Million Bought Deal Offering | Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Antibe Therapeutics Inc. (TSXV: ATE) ("Antibe" or the "Company") announced that it closed its previously announced bought deal public offering of 62,500,000 units of t... |
| - | Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China | NEWS PROVIDED BY Nuance Pharma Feb 09, 2021, 07:00 ET SHARE THIS ARTICLE TORONTO and SHANGHAI, Feb. 9, 2021 /PRNewswire/ -- Antibe Therapeutics Inc. (TSX: ATE,OTCQB: ATBPF) today announced that it has licensed otenaproxesul to Nuance ... |